Travel-related MERS-CoV cases: an assessment of exposures and risk factors in a group of Dutch travellers returning from the Kingdom of Saudi Arabia, May 2014

Ewout B Fanoy1,2,3,13*, Marianne AB van der Sande1,4, Marleen Kraaij-Dirkzwager1, Kees Dirksen1, Marcel Jonges1, Wim van der Hoek1, Marion PG Koopmans6, Douwe van der Werf7, Gerard Sonder8, Charlie van der Weijden9, Jet van der Heuvel10, Luc Gelinck11, Jolande W Bouwhuis12, Arianne B van Gageldonk-Lafeber1 and on behalf of the members of the MERS-CoV outbreak investigation team of The Netherlands

Abstract

Background: In May 2014, Middle East respiratory syndrome coronavirus (MERS-CoV) infection, with closely related viral genomes, was diagnosed in two Dutch residents, returning from a pilgrimage to Medina and Mecca, Kingdom of Saudi Arabia (KSA). These patients travelled with a group of 29 other Dutch travellers. We conducted an epidemiological assessment of the travel group to identify likely source(s) of infection and presence of potential risk factors.

Methods: All travellers, including the two cases, completed a questionnaire focussing on potential human, animal and food exposures to MERS-CoV. The questionnaire was modified from the WHO MERS-CoV questionnaire, taking into account the specific route and activities of the travel group.

Results: Twelve non-cases drank unpasteurized camel milk and had contact with camels. Most travellers, including one of the two patients (Case 1), visited local markets, where six of them consumed fruits. Two travellers, including Case 1, were exposed to coughing patients when visiting a hospital in Medina. Four travellers, including Case 1, visited two hospitals in Mecca. All travellers had been in contact with Case 1 while he was sick, with initially non-respiratory complaints. The cases were found to be older than the other travellers and both had co-morbidities.

Conclusions: This epidemiological study revealed the complexity of MERS-CoV outbreak investigations with multiple potential exposures to MERS-CoV reported such as healthcare visits, camel exposure, and exposure to untreated food products. Exposure to MERS-CoV during a hospital visit is considered a likely source of infection for Case 1 but not for Case 2. For Case 2, the most likely source could not be determined. Exposure to MERS-CoV via direct contact with animals or dairy products seems unlikely for the two Dutch cases. Furthermore, exposure to a common but still unidentified source cannot be ruled out. More comprehensive research into sources of infection in the Arabian Peninsula is needed to strengthen and specify the prevention of MERS-CoV infections.

Keywords: Middle East respiratory syndrome coronavirus, MERS, MERS-CoV, Exposure, Risk factors, Epidemiology
Background
In 2012, the Middle East respiratory syndrome coronavirus (MERS-CoV) was isolated for the first time from the sputum of a 60-year-old man who presented with an acute pneumonia in Kingdom of Saudi Arabia (KSA) [1]. As of June 24 2014, 707 laboratory-confirmed cases of MERS-CoV infection have been reported to the WHO including 252 (36%) fatal cases [2]. Following the first upsurge of cases in spring 2013, a second wave occurred in 2014, mainly in KSA [3]. Most cases so far either resided in or travelled to the Arabian Peninsula and neighbouring countries or were close contacts of these cases. Furthermore, travel related cases have been reported from the United States of America (USA), the United Kingdom (UK), Germany, France, Tunisia, Italy, Greece, Algeria, Egypt, the Philippines and Malaysia [3-7].

So far, mainly sporadic cases are reported as well as a few hospital outbreaks, which is in line with a low reproduction rate (R0) of MERS-CoV, estimated to range from 0.4 to 1.5 [8-10]. The median incubation period is estimated to be 5.2 days (95% CI 1.9-14.7 days) [8]. For most non healthcare associated cases no clear source of infection could be identified, although camels are considered a reservoir as the virus and antibodies against MERS-CoV have been identified in camels (Camelus dromedarius) and in their milk [9,10]. The exact modes of transmission of the virus to humans remain unclear [11-14], leaving the possibility for other yet unidentified sources of infection. To stop or reduce transmission of MERS-CoV and prevent new human infections, it is important to identify all potential sources of infections as well as risk factors and route(s) of transmission.

In May 2014, MERS-CoV infection was diagnosed in two Dutch residents. These cases travelled with a group of 29 other people, returning to the Netherlands from pilgrimage to Medina and Mecca, KSA [15]. We conducted a comprehensive epidemiological assessment of the travel group aiming to identify the likely source(s) of infection and presence of potential risk factors for these two cases.

Methods
We compiled a questionnaire based on sample questionnaires originating from two WHO-protocols aimed to asses risk factors and investigate contacts of patients with MERS-CoV infection [16,17]. We adapted the questionnaire to the specific route and activities of the Dutch travellers. Our questionnaire covered human, animal and food exposures to MERS-CoV during the whole trip to KSA. The questionnaires consisted of 28 open and closed questions, and it took approximately 20 minutes to complete the face-to-face interview with the travellers (Additional file 1). Nurses of the public health services administered the questionnaires approximately 3 weeks after return to the Netherlands. For the two cases the questionnaire was completed with data on the travel route and stay in KSA collected by the National Coordination Centre for Communicable Disease Control.

Results
The patients were a 70-year-old man (Case 1) and his 73-year-old sister (Case 2), both having underlying cardiovascular co-morbidities and diabetes mellitus. The remaining travel group included 29 persons (41% male) aged between 10 and 70 years (median age: 55 years). Seventeen (59%) of the non-cases did not report any co-morbidities (Table 1). Upon identification of Case 1, throat swabs of all contacts were tested by PCR to assess other MERS-CoV cases. Apart from Case 2, who had reported mild respiratory complaints starting on the 5th of May (t = day 9), all other 29 travellers tested negative and did not develop symptoms.

Travel route exposures
The group made a pilgrimage to Medina and Mecca, KSA (Figure 1). They arrived on the 26th of April 2014 (day 0) in Medina, left by private bus to Mecca on the 4th of May (day 8) and returned to Amsterdam on the 10th of May (day 14). Case 1 started to feel feverish and had diarrhoea on the 1st of May (day 5). Respiratory complaints started on the 10th of May (day 14). MERS-CoV was identified in Case 1 on the 13th of May (day 17) and in Case 2 on the 14th of May (day 18). Detailed case reports of the two patients are described by Kraaij et al. [15]. During their pilgrimage, the whole group stayed in the same hotels and had breakfasts together. There was no fixed collective travel programme, but they had some joint visits to several mosques. The travellers also spent time alone or in smaller subgroups, visiting different mosques, markets and restaurants.

The exposures for both the cases and 29 asymptomatic travellers during their visit to Saudi Arabia are summarized in Table 2.

Animal exposure
On the 3rd of May (day 7), 12 travellers (excluding the two cases) made a trip to the touristic valley Wadi-e-Jinn, and stopped when they came across a herd of camels laying behind an improvised razor fence. Four travellers reported direct contact with the camels. Eight travellers mentioned indirect contact, for example via the fences surrounding the animals. Eleven travellers consumed unpasteurized camel milk, offered to them by the caretakers of the camels. Besides contact with camels, two travellers reported that they spotted many pigeons in the cities and fed them. No other direct contact with animals was mentioned.
Food exposure
As mentioned above, eleven travellers, excluding the two cases, consumed unpasteurized camel milk. Furthermore, 22 travellers, including Case 1, visited one or more local markets in Medina. Seven of them, excluding Case 1, bought and consumed a range of fruits such as prunes and dates. Furthermore, 14 travellers bought souvenirs, such as dates, perfume and clothing on these markets.

Human exposures
Hospital exposures
Case 1 and his son visited two hospitals in Medina on the 29th of April (day 3) because of eye complaints of the son. As mentioned before, they spent 45 minutes in a crowded waiting room of a general hospital where they were exposed to coughing patients. Subsequently, the son was referred to a specialized eye clinic where they spent no time in a waiting room and did not notice any coughing patients.

On the 5th of May (day 9), Case 1, accompanied by his son, visited an emergency department of a general hospital in Mecca because of acute malaise, weakness, nausea and diarrhoea (without respiratory complaints). These symptoms started on May 1 (day 5). Case 1 and his son spend 30-45 minutes in the waiting room, though they had no specific exposure to coughing people. On the 7th of May (day 11) Case 1 returned to another hospital in Mecca, accompanied by his son, where he only briefly stayed in the waiting room, received antibiotic treatment and was observed for approximately three hours. Four other travellers, including his son, accompanied him. Two of them did not notice any coughing persons, while the other two did not answer this question. Case 2 did not visit a hospital during the pilgrimage or prior to her diagnosis in the Netherlands.

Contact with coughing persons
Two travellers (Case 1 and his son) waited 45 minutes in a crowded waiting room of a general hospital in Medina (29th of April, day 3) where they were exposed to coughing patients. One other traveller, who did not enter a hospital, reported coughing persons outdoors. The duration and intensity of this contact was not clarified in more detail. Case 1 and 2 had been in close contact with each other during the entire trip, as they shared hotel rooms.

All 29 travellers had been in contact with both cases during the trip. Seventeen travellers had minimal social contact with the two cases, for example only brief eye contact in the hotel lobby or in the bus. Twelve travellers reported daily contact, such as visits to the hotel room of Case 1 while he was sick, or accompanying him while shopping. The son of Case 1 had the most intensive

Table 1 Self-reported co-morbidity for the 31 persons who made a pilgrimage to Medina and Mecca, Kingdom of Saudi Arabia, April-May 2014

| Co-morbidity           | MERS-CoV patients | Other travellers |
|------------------------|-------------------|-----------------|
|                        | N = 2             | N = 29          |
|                        | n (%)             | n (%)           |
| Cardiovascular diseases | 2 (100)           | 4 (14)          |
| Diabetes mellitus      | 2(100)            | 6 (21)          |
| Other co-morbidity*    | 0 -               | 9 (31)          |
| No co-morbidities      | 0 -               | 12 (41)         |

*Mainly allergy reported.

Table 2 Overview of potential MERS-CoV exposures of cases and asymptomatic travellers during a visit to the Kingdom of Saudi Arabia, April 26th - May 10th 2014

| Animal exposure                  | Case 1 | Case 2 | Asymptomatic travellers (n = 29) |
|----------------------------------|--------|--------|---------------------------------|
| Visit to camel farm              | No     | No     | 14 (48%)                        |
| Direct contact with camels       | No     | No     | 4 (14%)                         |
| Indirect contact with camels     | No     | No     | 8 (28%)                         |
| Food exposures                   |        |        |                                 |
| Consumption of unpasteurized milk| No     | No     | 11 (38%)                        |
| Visit to local market in Medina  | Yes    | No     | 21 (72%)                        |
| Consumption of fruits on market  | No     | No     | 7 (24%)                         |
| Buying souvenirs on market        | No     | No     | 14 (48%)                        |
| Human exposures                  |        |        |                                 |
| Contact with coughing patients (excluding case 1 and 2) | Yes, in waiting room of a hospital | No | 2 (7%) |
| Hospital visit (due to other non-MERS related illnesses) | Yes | No | 1 (3%) |
| Minimal social contact with case 1 and/or 2 | Case 1 and 2 had daily contact with each other | 17 (59%) |
| Daily contact with case 1 and/or 2 | Case 1 and 2 had daily contact with each other and shared hotel rooms | 12 (41%) |

MERS-CoV: Middle East Respiratory Syndrome coronavirus.
contact sharing a hotel room with both cases. Nevertheless, his throat swabs tested negative to MERS-CoV by PCR during the follow-up after the identification of Case 1.

**Discussion**

We found no indications that the two cases were infected via contact with specific animals or dairy products. Infection during a hospital visit could be a source for Case 1. Sequence analysis of parts of the viral genome collected from both patients had shown that the strains were nearly identical, suggesting that the cases have infected each other, or that they were exposed to a common source. In the latter case, exposure during a hospital visit is unlikely because Case 2 did not visit a hospital before onset of disease. The possibility of asymptomatic infections and transmission among the accompanying travellers cannot be ruled out, but seems unlikely in view of the negative PCR results. Subsequently, although considered unlikely, we cannot exclude the possibility of asymptomatic travellers being a source of infection for Case 1 and/or 2. No other common sources were identified although we cannot exclude the possibility of lack of accurate recall or indirect exposure to animal excreta. It might be possible that one or both cases were infected during non-specific contacts with the local population or the environment. If initial zoonotic introductions of MERS-CoV from camels have been followed by low level presence among the (asymptomatic) population or in the environment at large, this might result in an ongoing community-based outbreak, which, unlike SARS, cannot be controlled by rigorous hospital hygiene alone.

Both patients were of older age and had comorbidities. In general, older age and comorbidity are considered risk factors for symptomatic MERS-CoV infections, although this was not the case in all outbreaks [18,19]. In this study, the distribution of symptoms towards higher age and comorbidity fits this assumption. Ongoing serological analysis upon travellers and people exposed to the case in the Netherlands may reveal to what extent asymptomatic infection has occurred. The remainder of the travellers did not develop symptomatic MERS-CoV and did not have positive PCR-test results despite exposure to camels, dairy products and the two cases. This could point to a low transmissibility of the virus, which is also illustrated by the limited number of secondary infections among contacts of import cases described elsewhere, with the reservation that asymptomatic infections among the remaining travellers cannot be excluded fully as final serologic results are not available [5,6]. Currently, there is only limited epidemiological information published considering potential sources and transmission dynamics of MERS-CoV infection within the Arabian Peninsula. Descriptive studies among a well-defined group of travellers can therefore provide relevant epidemiologic information, even when the number of travellers is too small to draw definite conclusions. More in depth epidemiological investigation of comparable travel groups will add to the body of evidence, although the diversity of activities during a relatively short trip makes accurate recall of potential exposure challenging. Alternatively, prospective cohort studies among travellers to affected areas, whereby travellers are asked to keep a daily diary, are likely to be more informative and complete. Due to the uncertainty about the source, the detailed questions of the WHO-questionnaire were a very useful guide to decide on the most relevant exposures to be explored, adapted to the specific route of travel.

**Conclusions**

The exact source of infection remains difficult to identify. Case 1 could have been infected during his visit to a
hospital and subsequently have infected Case 2. However, exposure to a common source for both Case 1 and 2 cannot be ruled out. Besides, Case 1 may have been exposed to a yet unidentified source and subsequently have infected Case 2, or vice versa. More research to relevant sources in the Arabian Peninsula is needed. The suggested role of underlying disease to develop MERS-CoV infection is in line with the age and comorbidity of the two Dutch cases and the absence of symptomatic MERS-CoV infections among the younger and healthier travellers.

Acknowledgements
We thank Lieke Wielders and Martí de Lange for assisting with development of the questionnaires and Margreet te Wierik and Kositas Danis for commenting on the manuscript. We also express our thanks to the nurses of Public Health Services of Amsterdam, Flevoland, Haaglanden, Hart voor Brabant and Usselland for conducting the questionnaires.

Author details
1National Institute for Public Health and the Environment, Centre for Infectious Disease Control, Bilthoven, The Netherlands. European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control, Stockholm, Sweden. 2Public Health Service region of Utrecht, Zeist, The Netherlands. 3Julius Center, University Medical Center, Utrecht, Utrecht, The Netherlands. 4Public Health Service Haaglanden, Den Haag, The Netherlands. 5Erasmus Medical Center, Rotterdam, The Netherlands. 6Public Health Service Usselland, Zwolle, The Netherlands. 7Public Health Service Amsterdam, Amsterdam, The Netherlands. 8Public Health Service Flevoland, Lelystad, The Netherlands. 9Public Health Service Hart voor Brabant, Hertogenbosch, The Netherlands. 10Medical Centre Haaglanden, The Hague, The Netherlands. 11Isalaklinieken, Zwolle, The Netherlands. 12National Institute for Public Health and the Environment, Epidemiology and Surveillance Unit, Antonie van Leeuwenhoeklaan 9, Bilthoven, NA 3721, The Netherlands.

Received: 30 June 2014 Accepted: 2 October 2014 Published: 17 October 2014

References
1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA: Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012, 367(19):1814–1820.
2. Organization WH: Coronavirus Infections Global Alert and Response (GAR), 2014. Available from: http://www.who.int/csr/disease/coronavirus_infections/en/.
3. ECDC: Epidemiological Update: Middle East Respiratory Syndrome Coronavirus (MERS-CoV) 2014 [June 16 2014]; Available from: http://www.ecdc.europa.eu/en/press/news/_layouts/forms/News_DispForm.aspx?st=ded73296ef62d476c-9133-18f64cb1b568dD10=0116.
4. Bialek SR, Allen D, Alvardo-Ramy F, Arthur R, Balajee A, Bell D, Best S, Blackmore C, Breakwell L, Cannons A, Brown C, Cetron M, Chea N, Chommanard C, Cohen N, Conover C, Crespo A, Creswittin J, Curn M, Dahl R, Dealter S, DelMarla A, Echols F, Erdman DD, Feikind D, Fries M, Gerber Sk, Gulati R, Hale C, Hayden LM, et al. First confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection in the United States, updated information on the epidemiology of MERS-CoV infection, and guidance for the public, clinicians, and public health authorities - May 2014. MMWR Morb Mortal Wkly Rep 2014, 63(19):431–436.
5. Pebody RG, Chand MA, Thomas HL, Green HK, Biddockling NL, Carvalho C, Brown CS, Anderson SP, Bosuyee C, Crawley-Bovey E, Irving DJ, Arvons E, Tong C, Newsholm W, Price N, Langrith C, Tucker D, Zhao H, Phin N, Crofts J, Berringham A, Gilgum-Jones E, Brown KE, Evans B, Catchpole M, Watson JM: The United Kingdom public health response to an imported laboratory confirmed case of a novel coronavirus in September 2012. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 2012, 17(40):2092.
6. Puzelli S, Asiea A, Santini MG, Di Martino A, Facchini M, Castrucci MR, Meola M, Arvia C, Corpilli F, Pierucci S, Barreti R, Bartoloni A, Bartolozzi D, Di Martino M, Galli L, Pompa MG, Rezza G, Balocchi E, Donatelli I: Investigation of an imported case of Middle East respiratory syndrome coronavirus (MERS-CoV) infection in Florence, Italy, May to June 2013. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 2013, 18(34):2–5.
7. Tsiodras S, Baka A, Mentis S, Illouposoulos D, Dedoukou X, Papamavrou G, Karadima S, Emmanouil M, Kossayakis A, Spanakis N, Pavli A, Maltezou H, Karageorgou A, Spala G, Pitrirga V, Kosmas E, Tsagilis S, Skatskas S, Koulouris N, Koutsouikou A, Bakakos P, Markozinadis E, Dionellis G, Pountis K, Rovina N, Kyrkakopoulou M, Estrahoiou P, Papadimitrou T, Kremastinou J, Tsakris A, Saroglou G: A case of imported Middle East respiratory syndrome coronavirus infection and public health response, Greece, April 2014. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 2014, 19(16):20782.
8. Guery B, Poissy J, el Mansourf L, Sejourn J, Etahar N, Lemaire X, Vuotto F, Goffard A, Behrill S, Enouf V, Caro V, Maileis A, Che D, Manuguena JC, Mathieu D,
Fanoy A, van der Werf S, group ME-Cs. Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission. *Lancet* 2013, 381(9885):2265–2272.

9. Reusken CB, Haagmans BL, Muller MA, Gutierrez C, Godeke GJ, Meyer B, Muth D, Raj VS, Smits-De Vries L, Corman VM, Drexler JF, Smits SL, De Tahir YE, De Sousa R, van Beek J, Nowotny N, van Maassen K, Hidalgo-Hermoso S, Bosch BJ, Rottier P, Osterhaus A, Gorraiz-Schmidt C, Drosten C, Koopmans MP. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. *Lancet Infect Dis* 2013, 13(10):859–866.

10. Reusken CBEM ML, Feyisa A, Ullaramu H, Godeke G-J, Danmarwa A, Dawo F, Jernli M, Melaku S, Shamaki D, Woma Y, Wungak Y, Gebremedhin EZ, Zutt I, Bosch B-J, Haagmans BL, Koopmans MP. Geographic distribution of MERS coronavirus among dromedary camels, Africa. *Emerg Infect Dis* 2014, 20(1):1370–1374.

11. Haagmans BL, Al Dhahiry SH, Reusken CB, Raj VS, Galiano M, Myers R, Godeke GJ, Jonges M, Farag E, Diab A, Ghobashy H, Al-Thani M, Al-Marri SA, Al Romaihi HE, Al Khal A, Bermingham A, Osterhaus AD, AlHajri MM, Koopmans MP. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. *Lancet Infect Dis* 2014, 14(2):140–145.

12. Memish ZA, Cotten M, Meyer B, Watson SJ, Aljarah A, Al Rabeeah AA, Corman VM, Sieberg A, Makhdoum HQ, Assiri A, Al Masri M, Alabdabagh S, Bosch BJ, Beer M, Muller MA, Killam P, Drosten C. Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia, 2013. *Emerg Infect Dis* 2014, 20(6):1012–1015.

13. Meyer B, Muller MA, Corman VM, Reusken CB, Ritz D, Godeke GJ, Lattwein E, Sina Si, Siemens A, van Beek J, Drexler JF, Muth D, Bosch BJ, Wernery U, Koopmans MP, Wernery R, Drosten C. Antibodies against MERS coronavirus in dromedary camels, United Arab Emirates, 2003 and 2013. *Emerg Infect Dis* 2014, 20(4):552–559.

14. Reusken CB, Ababneh M, Raj VS, Meyer B, Eljarah A, Abutarbush S, Godeke GJ, Bestebroer TM, Zutt I, Muller MA, Bosch BJ, Rottier PJ, Osterhaus AD, Drosten C, Haagmans BL, Koopmans MP. Middle East respiratory syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013. *Euro Surveill* 2013, 18(30):20662.

15. Kraaij-Dijkstra M, Timen A, Dirksen K, Gelincik L, Leyten E, Groeneveld P, Jansen C, Jonges M, Raj S, Thurkow I, van Gageldonk-Lafeber R, van der Eijk A, Koopmans M. Netherlands ME-Coitot: Middle East respiratory syndrome coronavirus (MERS-CoV) infections in two returning travellers in the Netherlands, May 2014. *Euro Surveill* 2014, 19(21):1–7.

16. World Health Organization. Seroepidemiological Investigation of Contacts of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Patients 2013. Available from: http://www.who.int/csr/disease/coronavirus_infections/MERS-CoV_2014.pdf.

17. World Health Organization. Cari-Contact Study to Assess Potential Risk Factors Related to Human Illness Caused by Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Available from: http://www.who.int/csr/disease/coronavirus_infections/MERS-CoV_CaseControlStudyExposures28March2014.pdf.

18. Arabi YM, Arifi AA, Bakly HH, Najm H, Aldawood AS, Ghabashii A, Hawa H, Alothman A, Khaldi A, Al Raiy B. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. *Ann Intern Med* 2014, 160(6):389–397.

19. Al-Abdallat MM, Payne DC, Alqasrawi S, Rha B, Tohme RA, Abedi GR, Al Noor M, Iblan I, Jarour N, Farag NH, Haddadin A, Al-Sanouri T, Tamin A, Harcourt JL, Kuhar DT, Smerdon DL, Erdman DD, Pallansch MA, Haynes LM, Gerber SI. Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2014, pii: clu359 [Epub ahead of print].